The Experts below are selected from a list of 837 Experts worldwide ranked by ideXlab platform
Soldano Ferrone - One of the best experts on this subject based on the ideXlab platform.
-
association of high molecular weight Melanoma associated antigen expression in primary Acral Lentiginous Melanoma lesions with poor prognosis
Cancer Research, 1993Co-Authors: Toshiro Kageshita, Norikazu Kuriya, Tomomichi Ono, Takashi Horikoshi, Makoto Takahashi, George Y Wong, Soldano FerroneAbstract:In a recent study we detected marked differences in the antigenic profile of Acral Lentiginous Melanoma (ALM) and nodular Melanoma lesions. Furthermore, we showed that the human high molecular weight Melanoma-associated antigen (HMW-MAA) is expressed with a significantly higher frequency in metastatic than in primary ALM lesions. Because of the potential role of HMW-MAA in the metastatic process of Melanoma cells, in the present investigation we tested whether HMW-MAA represents a useful prognostic marker in ALM. Primary ALM lesions removed from 32 patients were stained with anti-HMW-MAA monoclonal antibody (mAb) in an immunoperoxidase reaction. The results were correlated with the expression of other markers defined by mAb, with clinical parameters of the disease, and with histopathological characteristics of the lesions. Only 9 of the 32 primary ALM lesions tested were stained by anti-HMW-MAA mAb. Expression of HMW-MAA was the only variable associated with patients' survival and disease-free survival. Both were significantly shorter in patients with HMW-MAA expression in their primary lesions. These results suggest that HMW-MAA may represent a novel prognostic marker in ALM, since phenotyping of primary ALM lesions with anti-HMW-MAA mAb may provide information about the prognosis of the disease which cannot be obtained with known prognostic parameters.
-
Differential expression of Melanoma associated antigens in Acral Lentiginous Melanoma and in nodular Melanoma lesions.
Cancer research, 1991Co-Authors: Toshiro Kageshita, Takashi Nakamura, Masanobu Yamada, Norikazu Kuriya, Tatsuyoshi Arao, Soldano FerroneAbstract:Abstract The reactivity in an avidin-biotin complex immunoperoxidase reaction with a large panel of anti-human Melanoma associated antigen (MAA) and anti-HLA monoclonal antibodies of 24 primary and 11 metastatic Acral Lentiginous Melanoma (ALM) lesions was compared to that of 12 primary and 12 metastatic nodular Melanoma (NM) lesions. The expression of the membrane bound vitronectin receptor, M r 110,000 MAA, M r 97,000 MAA, and intercellular adhesion molecule-1 was significantly lower in both primary and metastatic ALM lesions than in their NM counterparts. Furthermore, primary ALM lesions displayed a significantly lower expression than primary NM lesions of the membrane bound high molecular weight Melanoma associated antigen (HMW-MAA), M r 110,000 MAA, M r 100,000 MAA, 9- O -acetyl-G D3 , G D2 -G D3 , and G D2 , of the cytoplasmic monoclonal antibody 465.12 defined MAA and of transferrin receptor and of HLA-DQ and DP antigens; ALM metastases expressed a significantly lower level of carcinoembryonic antigen-MAA than NM metastases. These antigenic differences do not reflect an antigenic paucity of ALM cells, since ALM lesions express a higher level of T 4 -tyrosinase than NM lesions and a level of HLA Class I antigens similar to that of NM lesions. In view of the use of HMW-MAA, M r 97,000 MAA, and G D3 in immunoscintigraphy and/or in immunotherapy, it is noteworthy that the three antigens are expressed in a similar high percentage of ALM metastases and of primary and metastatic NM lesions, while the HMW-MAA is expressed in a markedly lower percentage of primary ALM lesions than M r 97,000 MAA and G D3 . However, the degree of heterogeneity of HMW-MAA within a positive primary ALM lesion, as measured by the percentage of stained Melanoma cells, is lower than that of M r 97,000 MAA and G D3 . The expression of the antigens investigated in ALM and NM lesions was not correlated with the presence of lymphocyte infiltrates, melanin content of Melanoma cells, and epithelioid and spindle type of Melanoma cells in the lesions. On the other hand, the survival of patients with ALM was inversely correlated with the expression of intercellular adhesion molecule 1 or HMW-MAA in their primary lesions. A potential role of HMW-MAA in the course of the disease is suggested by its significantly higher expression in metastatic than in primary ALM lesions. Since the expression of HMW-MAA in primary ALM lesions is not associated with known prognostic parameters, the present study suggests that expression of HMW-MAA may be an additional prognostic parameter in ALM, if the present results are confirmed in a large patient population.
Dale Han - One of the best experts on this subject based on the ideXlab platform.
-
Acral Lentiginous Melanoma do surgical approach and sentinel lymph node biopsy matter
Plastic and reconstructive surgery. Global open, 2020Co-Authors: Marc E Walker, Gang Han, Kyle S Gabrick, Jack Kanouzi, Anjela Galan, James Clune, Deepak Narayan, Stephan Ariyan, Dale HanAbstract:Management of Acral Lentiginous Melanoma (ALM) remains controversial. Traditionally, ALM was managed with digit amputation (DA), resulting in significant morbidity, but recent evidence has advocated for digit sparing management. Furthermore, the significance of nodal metastasis for ALM is not well reported. The aims of this study were to determine if surgical approach for primary ALM impacts outcomes and to evaluate the predictive value of nodal status for ALM. Methods Patients with localized ALM diagnosed from 1982 to 2017 were retrospectively identified. Clinicopathologic characteristics were correlated with surgical approach, nodal metastasis, overall survival, and recurrence-free survival. Results There were 47 patients with ALM. Median age was 59 years, and median thickness was 3 mm. 51% of patients underwent wide local excision (WLE), 27.9% underwent DA, and 20.9% underwent partial digit amputation (PDA). ALM on the hand versus foot (OR: 12.7, 95%, confidence interval (CI), 2.0-80.1; P = 0.007) and subungual versus nonsubungual location (OR: 28.0, 95% confidence interval, 2.7-295.7; P = 0.006) were significantly associated with surgical approach (DA and PDA versus WLE). There were no significant differences in overall survival or recurrence-free survival between DA, PDA, or WLE cases (P = 0.481 and P = 0.778, respectively). There were no significant differences in overall survival or recurrence-free survival based on nodal status (P = 0.562 and P = 0.136, respectively). Conclusions No significant differences in overall survival or recurrence-free survival were seen between ALM patients treated with DA, PDA, and WLE. Given these results, PDA or WLE may be options in select patients with digital ALM; however, careful consideration must be taken when deciding on the surgical approach.
-
does sentinel lymph node status have prognostic significance in patients with Acral Lentiginous Melanoma
Journal of Surgical Oncology, 2019Co-Authors: Sabrina Pavri, Gang Han, Sajid A Khan, Dale HanAbstract:BACKGROUND The prognostic benefit of sentinel lymph node biopsy (SLNB) and factors predictive of survival specifically in patients with Acral Lentiginous Melanoma (ALM) are unknown. METHODS The SEER database was queried for ALM cases that underwent SLNB from 1998 to 2013. Clinicopathological factors were correlated with SLN status, overall survival (OS), and Melanoma-specific survival (MSS). RESULTS Median age for the 753 ALM study patients was 65 years, and 48.2% were male. Median thickness was 2 mm with 38.1% of cases having ulceration. SLN metastases were detected in 194 of 753 cases (25.7%). Multivariable analysis showed that thickness, Clark level IV-V, and ulceration significantly predicted for SLN metastasis (P < 0.05). For patients with positive SLN, 5-year OS and MSS were significantly worse at 48.1% and 58.9%, respectively, compared with 78.7% and 88.5%, respectively, for patients with negative SLN (P < 0.0001). On multivariable analyses, older age, male gender, increasing thickness, ulceration, and a positive SLN significantly predicted for worse OS and MSS (all P < 0.05). CONCLUSION This study confirms the important role of SLNB in ALM. SLN metastases are seen in 25.7% of ALM cases, providing significant prognostic information. In addition, thickness, ulceration status, and SLNB status significantly predict survival in patients with ALM.
Toshiro Kageshita - One of the best experts on this subject based on the ideXlab platform.
-
the expression of human high molecular weight Melanoma associated antigen in Acral Lentiginous Melanoma
BioScience Trends, 2010Co-Authors: Hazuki Nishi, Toshiro Kageshita, Yuji Inoue, Minoru Takata, Hironobu IhnAbstract:The high molecular weight Melanoma-associated antigen (HMW-MAA) is a membrane-bound chondroitin sulphate proteoglycan that is highly expressed on the surface of Melanoma cells. It represents an attractive target for immunotherapy of malignant Melanoma. Previously, it was reported that HMW-MAA was detected in about 20-30% of primary Acral Lentiginous Melanoma (ALM) lesions by immunohistochemical staining (IHC) of frozen sections with monoclonal antibodies (mAbs). In the present study, we examined the expression of HMW-MAA in 95 paraffin-embedded, primary ALM lesions and 13 primary superficial spreading Melanoma (SSM) lesions. A total of 51 primary ALM lesions (53.6%) were positive for HMW-MAA. Almost all of these positive cases showed a weak staining intensity. On the other hand, all 13 primary SSM lesions were strongly positive for HMW-MAA expression. Our data showed that the staining intensity of HMW-MAA ALM lesions was weaker than that of SSM. Furthermore, the percentage of HMW-MAA positive staining in ALM lesions was higher than previously reported.
-
association of high molecular weight Melanoma associated antigen expression in primary Acral Lentiginous Melanoma lesions with poor prognosis
Cancer Research, 1993Co-Authors: Toshiro Kageshita, Norikazu Kuriya, Tomomichi Ono, Takashi Horikoshi, Makoto Takahashi, George Y Wong, Soldano FerroneAbstract:In a recent study we detected marked differences in the antigenic profile of Acral Lentiginous Melanoma (ALM) and nodular Melanoma lesions. Furthermore, we showed that the human high molecular weight Melanoma-associated antigen (HMW-MAA) is expressed with a significantly higher frequency in metastatic than in primary ALM lesions. Because of the potential role of HMW-MAA in the metastatic process of Melanoma cells, in the present investigation we tested whether HMW-MAA represents a useful prognostic marker in ALM. Primary ALM lesions removed from 32 patients were stained with anti-HMW-MAA monoclonal antibody (mAb) in an immunoperoxidase reaction. The results were correlated with the expression of other markers defined by mAb, with clinical parameters of the disease, and with histopathological characteristics of the lesions. Only 9 of the 32 primary ALM lesions tested were stained by anti-HMW-MAA mAb. Expression of HMW-MAA was the only variable associated with patients' survival and disease-free survival. Both were significantly shorter in patients with HMW-MAA expression in their primary lesions. These results suggest that HMW-MAA may represent a novel prognostic marker in ALM, since phenotyping of primary ALM lesions with anti-HMW-MAA mAb may provide information about the prognosis of the disease which cannot be obtained with known prognostic parameters.
-
Differential expression of Melanoma associated antigens in Acral Lentiginous Melanoma and in nodular Melanoma lesions.
Cancer research, 1991Co-Authors: Toshiro Kageshita, Takashi Nakamura, Masanobu Yamada, Norikazu Kuriya, Tatsuyoshi Arao, Soldano FerroneAbstract:Abstract The reactivity in an avidin-biotin complex immunoperoxidase reaction with a large panel of anti-human Melanoma associated antigen (MAA) and anti-HLA monoclonal antibodies of 24 primary and 11 metastatic Acral Lentiginous Melanoma (ALM) lesions was compared to that of 12 primary and 12 metastatic nodular Melanoma (NM) lesions. The expression of the membrane bound vitronectin receptor, M r 110,000 MAA, M r 97,000 MAA, and intercellular adhesion molecule-1 was significantly lower in both primary and metastatic ALM lesions than in their NM counterparts. Furthermore, primary ALM lesions displayed a significantly lower expression than primary NM lesions of the membrane bound high molecular weight Melanoma associated antigen (HMW-MAA), M r 110,000 MAA, M r 100,000 MAA, 9- O -acetyl-G D3 , G D2 -G D3 , and G D2 , of the cytoplasmic monoclonal antibody 465.12 defined MAA and of transferrin receptor and of HLA-DQ and DP antigens; ALM metastases expressed a significantly lower level of carcinoembryonic antigen-MAA than NM metastases. These antigenic differences do not reflect an antigenic paucity of ALM cells, since ALM lesions express a higher level of T 4 -tyrosinase than NM lesions and a level of HLA Class I antigens similar to that of NM lesions. In view of the use of HMW-MAA, M r 97,000 MAA, and G D3 in immunoscintigraphy and/or in immunotherapy, it is noteworthy that the three antigens are expressed in a similar high percentage of ALM metastases and of primary and metastatic NM lesions, while the HMW-MAA is expressed in a markedly lower percentage of primary ALM lesions than M r 97,000 MAA and G D3 . However, the degree of heterogeneity of HMW-MAA within a positive primary ALM lesion, as measured by the percentage of stained Melanoma cells, is lower than that of M r 97,000 MAA and G D3 . The expression of the antigens investigated in ALM and NM lesions was not correlated with the presence of lymphocyte infiltrates, melanin content of Melanoma cells, and epithelioid and spindle type of Melanoma cells in the lesions. On the other hand, the survival of patients with ALM was inversely correlated with the expression of intercellular adhesion molecule 1 or HMW-MAA in their primary lesions. A potential role of HMW-MAA in the course of the disease is suggested by its significantly higher expression in metastatic than in primary ALM lesions. Since the expression of HMW-MAA in primary ALM lesions is not associated with known prognostic parameters, the present study suggests that expression of HMW-MAA may be an additional prognostic parameter in ALM, if the present results are confirmed in a large patient population.
Kihoon Song - One of the best experts on this subject based on the ideXlab platform.
-
clinical features and prognosis of asian patients with Acral Lentiginous Melanoma who have nodal nevi in their sentinel lymph node biopsy specimen
Journal of The American Academy of Dermatology, 2018Co-Authors: Hojin Kim, Jeongwan Seo, Meesook Roh, Ji Hyun Lee, Kihoon SongAbstract:Abstract Background Nodal melanocytic nevi (NN) encountered during sentinel lymph node biopsy (SLB) for malignant Melanoma are usually difficult to distinguish from metastatic Melanoma. However, NN have not been studied well in Acral Lentiginous Melanoma (ALM) in Asian populations. Objective To investigate the clinical characteristics and significance of NN in SLBs from ALM patients. Methods We retrospectively analyzed 84 patients with ALM who underwent SLB between June 2010 and July 2017. Results Of the 84 ALM patients, 9 (10.7%) had NN in the SLB. NN were significantly more common in SLBs than in non-SLBs. The presence of pre-existing melanocytic lesions was found to be associated with NN (p Limitations The small sample size, single-center study design, and retrospective nature of the study were the limitations. Conclusion In Asian populations, the prevalence of NN in ALM is similar to that reported in Europe and the United States. The distant recurrence rate and overall survival in patients with ALM who have NN are similar to those of patients who do not have metastatic Melanoma.
-
prognostic and clinicopathologic associations of braf mutation in primary Acral Lentiginous Melanoma in korean patients a preliminary study
Annals of Dermatology, 2014Co-Authors: Jin Woo Hong, Suee Lee, Dae Cheol Kim, Ki Ho Kim, Kihoon SongAbstract:Background: In the majority of Melanomas, the RAS/RAF/ MEK/ERK signaling pathway is constitutively activated, due to oncogenic mutations in the BRAF and NRAS genes. The BRAF mutation has been mainly described in Caucasian Melanomas. However, there is a lack of study evaluating the status, and the clinical significance, of BRAF mutation in the Asian population. Objective: This study was aimed to determine the frequency of BRAF mutation, and to evaluate the correlation of BRAF status with clinicopathologic features and outcomes, in Korean primary Acral Lentiginous Melanoma (ALM) patients. Methods: ALM samples (n=36) were analyzed for the BRAF V600E mutation, by dual-priming oligonucleotide (DPO) based real-time polymerase chain reaction. The clinicopathologic features and prognosis of the patients were analyzed with BRAF mutation status. Results: The incidence of BRAF V600E mutation was 19.4% (7/36). The BRAF V600E mutations were not associated with clinicopathologic features, except for the age factor. All of the BRAF-mutant patients survived without recurrence or metastasis, and have a better clinical outcome than BRAF wild-type patients. Conclusion: In Korean primary ALM, a low frequency of BRAF mutation was shown; and BRAF mutation presented with a favorable prognosis. These results indicate that other distinctive genetic mechanisms may have more important roles in the development and progression of disease. Further multicenter study with large sample size is firmly needed, to confirm the results of our preliminary study.
Hiroshi Uchi - One of the best experts on this subject based on the ideXlab platform.
-
Acral Lentiginous Melanoma versus other Melanoma a single center analysis in japan
Journal of Dermatology, 2017Co-Authors: Maiko Wada, Takamichi Ito, Gaku Tsuji, Takeshi Nakahara, Akihito Hagihara, Masutaka Furue, Hiroshi UchiAbstract:We summarize herein our 14-year experience of conventional treatment outcomes before the era of molecular-targeted therapy and immunotherapy. Specifically, we conducted a retrospective review of our 252 patients with primary cutaneous Melanoma (Acral Lentiginous Melanoma [ALM], n = 121; non-Acral Lentiginous Melanoma [non-ALM], n = 131), and compared the prognostic factors between ALM and non-ALM. Melanoma-specific survival and disease-free survival were estimated using the Kaplan–Meier method. Regarding the results, all patients were Japanese (106 male and 146 female), with a mean age of 60.1 years. Among ALM patients, age was elder and primary tumor size was larger than non-ALM. As for tumor thickness, in situ lesions were more frequently observed in ALM. There was no significant difference in the distribution of tumor thickness between the two groups when excluding the in situ lesions. For treatment of the primary Melanoma, 248 patients (98.4%) had undergone curative surgical excision and 120 patients with more than 1 mm or ulcerated Melanoma had undergone sentinel lymph node biopsy. Patients with systemic metastasis primarily underwent dacarbazine-based chemotherapy. The Kaplan–Meier survival curves revealed no significant difference in Melanoma-specific survival and disease-free survival between those with ALM and non-ALM. The results also showed that both ALM and non-ALM, when they initially metastasize, first affect the regional lymph nodes. Incisional biopsy was not an adverse prognostic factor. These results suggest that ALM does not differ in its biological behavior from non-ALM, so we can consider ALM as being equivalent to non-ALM. The initial treatment for ALM and non-ALM can involve the same strategy.
-
Acral Lentiginous Melanoma who benefits from sentinel lymph node biopsy
Journal of The American Academy of Dermatology, 2015Co-Authors: Takamichi Ito, Maiko Wada, Takeshi Nakahara, Akihito Hagihara, Masutaka Furue, Konosuke Nagae, Misa Nakanonakamura, Hiroshi UchiAbstract:Background There are significant clinicopathological, genetic, and biological differences between Acral Lentiginous Melanoma (ALM) and other types of Melanoma. Objective We sought to investigate the use of sentinel lymph node (SLN) biopsy for patients with ALM. Methods This was a retrospective review of 116 patients with primary ALM. Melanoma-specific and disease-free survival were estimated using the Kaplan-Meier method, together with multivariate analyses using the Cox proportional hazards regression model. Results All patients were Japanese (48 male and 68 female). Metastases in SLN were noted in 13 of 84 patients who underwent SLN biopsy. No patients with thin ALM (≤1 mm) and only 2 patients with nonulcerated ALM had tumor-positive SLN. Patients with positive SLN had significantly shorter Melanoma-specific survival (5-year survival rate, 37.5% vs 84.3%; P P = .0024). Among patients with thick (>1 mm) ALM, the influence of SLN positivity on Melanoma-specific survival was increased (5-year survival, 22.7% vs 80.8%; P = .0005). Limitations This was a retrospective study and had a small sample size. Conclusions SLN biopsy should be considered for patients with thick or ulcerated ALM. For patients with thin or nonulcerated ones, it may be of limited importance.
